Please login to the form below
depression
This page shows the latest depression news and features for those working in and with pharma, biotech and healthcare.
Allergan wins support against dissident shareholders
These struggles were compounded last month when it announced the phase 3 failure of its brightest pipeline hope, depression treatment rapastinel.
Latest news
-
Voice biomarker device could diagnose depression, heart disease
Sonde Health raises $16m in series A round. Technology that detects ‘vocal biomarkers’ from just a few seconds of speech could soon help speed up diagnosis of conditions such as depression ... Sonde says its main focus is on depression, as well as a
-
Sage’s postpartum depression treatment Zulresso gains US approval
First approval of its kind. The FDA has approved Sage Therapeutics’ treatment for postpartum depression, Zulresso (brexanolone). ... Zulresso is the first product specifically indicated for postpartum depression PPD, which can start during pregnancy or
-
Depression drug failure adds to Allergan's woes
Axe hangs over remaining monotherapy and suicidality trials
-
J&J’s Spravato breaks depression drought at FDA
The FDA has approved Johnson &Johnson’s Spravato for treatment-resistant depression, making it the first new-mechanism antidepressant to be licensed in decades. ... At the moment the only FDA-approved drug for treatment-resistant depression is Eli
-
Sage raises $575m ahead of FDA review date for Zulresso
A. modulator Zulresso (brexanolone) as a fast-acting, intravenous therapy for post-partum depression (PPD), and should get a verdict from the regulator by 19 March. ... It is also in earlier-stage studies for MDD plus insomnia as a maintenance therapy
More from news
Approximately 23 fully matching, plus 289 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
There were also significant improvements for AbbVie’s drug over Humira on quality of life measures and over Stelara on anxiety and depression, and risankizumab did better than both comparator drugs
-
AstraZeneca’s oncology renaissance
This saw phase 3 flops of drugs for stroke, prostate cancer and depression – failures that dented confidence in the firm as patent expiries for its blockbusters Crestor and Nexium loomed on
-
Health on instalment
But the Depression annihilated all that refinance money overnight, leaving millions in the lurch. ... to Wall Street and institutional investors - in a strategy not unlike how mortgages were lengthened during the Great Depression.
-
Speech therapy
The first of these studies looked at ‘Woebot’, a Facebook Messenger bot delivering text-based cognitive behavioural therapy, which successfully reduced self-reported symptoms of depression in its users.
-
Finding the patient voice
With chronic conditions (15%) or fighting mental illness like depression (12%), most of them hope to find a permanent solution by joining a trial.
More from intelligence
Approximately 0 fully matching, plus 25 partially matching documents found.
Latest appointments
-
Clark Health Communications expands team
director in a role that will see her lead teams responsible for driving the delivery of CHC’s gastroenterology, women’s health, depression and anticoagulants business.
-
Dr Niall Murphy and Pierre Schwich join Pharnext
Prior to this, Dr Murphy served as a unit leader for a team of scientists collaborating on research in the areas of addition biology, Alzheimer's disease, anxiety, depression and neurotoxicity
-
Turing names Eliseo Salinas as head of R&D
Salinas has played a leading role in numerous programmes for a range of diseases and disorders, with specific focus on central nervous systems (CNS) condition such as depression and anxiety, schizophrenia,
-
Lundbeck promotes Andreas Eggert and Klaus Abel to senior commercial roles
vortioxetine for major depression and Selincro (nalmefene) for alcohol dependence. ... including a once-monthly aripiprazole formulation for the treatment of schizophrenia and brexpiprazole (OPC-34712) for the treatment of schizophrenia and major
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Body image and mental health: The psoriasis connection
It’s part of who I am now and that’s fine.I struggled with anxiety for a long time and had a bout of depression which were independent from the
-
The problem with the ‘recovery’ conversation in mental health
However, since then, there have been great efforts to find treatments for a variety of mental illnesses, such as depression and anxiety. ... At least half of those that ‘recover’ from their first episode of depression will experience one or more
-
Havas Lynx shines spotlight on “invisible army” of carers to mark Carer’s Rights Day with powerful three-part podcast series
A study found that carers’ depression was statistically reduced after participating in a support group.
-
World Diabetes Day: Interaction and impact of diabetes on mental health
Depression exists in one in five adult diabetics (14), and diabetes distress affects one third of adult diabetics [15]. ... Diabetes distress is distinct from depression as it is caused by the emotional burden of managing diabetes [15].
-
Healthcircle
DermatologyAnalgesia. Anti-psychotics. Cancer Supportive-care. OTC &Consumers. Pain. Acne. Arthritis. Dandruff. Depression.
More from PMHub
Approximately 3 fully matching, plus 24 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Salary TBC
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Head of Partnerships - Competitive - London
-
Competitive Salary Offered
-
Midweight Brand Planner
-
Up to £50, 000
- NEW FREELANCE OPPORTUNITIES!!! LONDON and HOME WORKING!
-
EXCELLENT DAY RATES AVAILABLE
Subscribe to our email news alerts
- Health comms agency emotive hires new cell and gene therapy leader
- Success breeds success
- RNA-focused biotech Storm Therapeutics raises extra £14m
- Europe responding to gene therapy challenge, but picture remains fragmented
- Turning learning into action: The challenge of behaviour change
- Syncona launches another cell therapy company, Treg specialist Quell
PMHub
Synergy Vision
Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...
Latest intelligence
- Success breeds success
- This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
- Turning learning into action: The challenge of behaviour change
- ...
- Investing in our People
- As a small, boutique agency we can and do invest heavily in our team, who produce amazing results for our clients....
Quick links
Infographics
